Impact of head and neck malignancies on risk factors and survival in systemic lupus erythematosus

Chang, Shih‐Lun; Hsu, Hsin Te; Weng, Shih‐Feng; Lin, Yong-Song

doi:10.3109/00016489.2013.800228

Cited by 16 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLE patients are at increased risk of other types of malignancy including head and neck, thyroid and liver. (Table 1) A recent study [84] reported a SIR for head and neck cancers of 2.16 (95% CI, 1.13-4.13) in SLE, consistent with previous data. [17] However, both of these studies were in Asian populations (which have a higher general population risk for head and neck malignancy), therefore the relevance of these data to North American and European SLE populations is uncertain.…”

Section: Other Cancers With Increased Risksupporting

confidence: 89%

Cancer and Systemic Lupus Erythematosus

Ladouceur¹,

Tessier‐Cloutier²,

Clarke³

et al. 2020

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Link to publication on Research at Birmingham portal General rightsUnless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.• Users may freely distribute the URL that is used to identify this publication.• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.• User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) • Users may not further distribute the material nor use it for the purposes of commercial gain.Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.When citing, please reference the published version. Take down policyWhile the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

show abstract

Section: Other Cancers With Increased Risksupporting

confidence: 89%

Cancer and Systemic Lupus Erythematosus

Ladouceur¹,

Tessier‐Cloutier²,

Clarke³

et al. 2020

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

show abstract

“…Several individual cohort studies have reported that the risk of non-hematologic malignancies such as lung [1-3, 5, 6, 9, 33], liver [2-4, 6, 34], head and neck [3, 5, 10], thyroid [1-3, 35], vaginal/vulvar [1-4, 6], cervical (cancerous and pre-cancerous) [3, 4, 7, 12, 13, 36-42], dermatologic [3-5, 19], bladder or renal [2-4, 14, 43], anal [4, 13], and pancreatic [3, 13] are also increased in SLE.…”

Section: Malignancy Risk In Adult Slementioning

confidence: 99%

“…Chang et al [10] in a study involving 8,751 Taiwanese patients with SLE reported an incidence rate ratio (IRR) of 2.16 (1.13–4.13) for head and neck malignancies. The incidence of head and neck cancers was highest in the oral cavity (5 of 11 cancers, 45.45%) followed by the nasopharynx (4 of 11, 36.36%).…”

Section: Malignancy Risk In Adult Slementioning

confidence: 99%

“…However, there was no actual measurement of HPV status in this cohort. Many other cohort studies have also reported an increased frequency of HPV-associated malignancies [1-7, 10, 13, 36-40], without actually measuring HPV as a risk factor. An increased rate of HPV infection could also be responsible for the increased frequency of cervical dysplasia in women with SLE.…”

Section: Factors Potentially Mediating Riskmentioning

confidence: 99%

See 1 more Smart Citation

A review on SLE and malignancy

Choi

Flood

Bernatsky

et al. 2017

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. It predominantly affects young and middle-aged women. While improvements in the diagnosis and treatment of SLE have altered prognosis, morbidity and mortality rates remain higher than the general population. In addition to renal injury, cardiovascular disease, and infection, malignancy is known to be a significant cause of death in this population. There is increasing evidence to suggest that patients with SLE have a slightly higher overall risk of malignancy. The risk of malignancy in SLE is of considerable interest because the immune and genetic pathways underlying the pathogenesis of SLE and the immunosuppressant drugs (ISDs) used in its management may mediate this altered risk. Our current understanding of these and other risk factors and the implications for treating SLE and screening for malignancy is still evolving. This review summarizes the association between SLE and malignancy. The first section discusses the risk of overall and site-specific malignancies in both adult- and pediatric-onset SLE. Next, we evaluate the risk factors and possible mechanisms underlying the link between malignancy and SLE, including the use of ISDs, presence of certain SLE-related autoantibodies, chronic immune dysregulation, environmental factors, and shared genetic susceptibility. Finally, we review guidelines regarding cancer screening and vaccination for human papilloma virus.

show abstract

“…Specific Autoimmune (AI) diseases have also been associated with predisposing individuals to and increasing cancer risk as seen in a broad review [8] . A myriad of studies that included oral cancer patients saw an increased risk of oral malignancies due to the presence of AI disease, while a few dissented and contradicted those findings [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] .…”

Section: Introductionmentioning

confidence: 99%

Peripheral blood values as predictors of autoimmune status in oral cavity squamous cell carcinoma

Pillai

Valero

Navas

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

Highlights Oral cancer is highly stratified by tumor as opposed to host characteristics. Host peripheral blood data can impact prognosis in oral cancer. Autoimmune diseases are macroscopic reflection of host immune dysregulation. A score was created known as AI score to depict host status. AI score was useful as a prognostic tool in oral cancer and should be more widely investigated.

show abstract

Impact of head and neck malignancies on risk factors and survival in systemic lupus erythematosus

Cited by 16 publications

References 19 publications

Cancer and Systemic Lupus Erythematosus

Cancer and Systemic Lupus Erythematosus

A review on SLE and malignancy

Peripheral blood values as predictors of autoimmune status in oral cavity squamous cell carcinoma

Contact Info

Product

Resources

About